How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: a real-world study

(2021) Debora Basile et al.   BREAST

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2021) Carmine De Angelis et al.   CLINICAL CANCER RESEARCH

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

(2021) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)

(2021) Aditya Bardia et al.   CLINICAL CANCER RESEARCH

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

(2021) Hope S Rugo et al.   LANCET ONCOLOGY

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

(2021) G.N. Hortobagyi et al.   ANNALS OF ONCOLOGY

Characterizing demographics, clinical, and genomic characteristics for U.S. patients with HR+, HER2- metastatic breast cancer following progression on a CDK4 and 6 inhibitor.

(2021) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

(2021) Massimo Cristofanilli et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

(2021) Zsuzsanna Kahan et al.   EUROPEAN JOURNAL OF CANCER

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis

(2021) Rikke Nørgaard Pedersen et al.   JNCI-Journal of the National Cancer Institute

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials

(2021) E. Munzone et al.   ESMO Open

Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial

(2020) Amelia McCartney et al.   CLINICAL CANCER RESEARCH

Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).

(2020) Seth Andrew Wander et al.   JOURNAL OF CLINICAL ONCOLOGY

Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies

(2020) Xia-qing Xu et al.   ACTA PHARMACOLOGICA SINICA

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

(2020) Richard S. Finn et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single‑center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database

(2020) Hong Yang et al.   Oncology Letters

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†

(2020) F. Cardoso et al.   ANNALS OF ONCOLOGY

Real-World outcomes of cyclin-dependent kinase inhibitors continued beyond first disease progression in hormone receptor-positive metastatic breast cancer

(2020) Akaolisa Samuel Eziokwu et al.   Clinical Breast Cancer

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

(2020) Ryohei Ogata et al.   Breast Cancer

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

(2020) M. Martin et al.   ANNALS OF ONCOLOGY

Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4 /6 Inhibitor Therapy

(2020) Madeline M. Cook et al.   ONCOLOGIST

CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

(2020) Ilenia Migliaccio et al.   CANCER TREATMENT REVIEWS

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

(2019) Liam Cornell et al.   Cell Reports

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

(2019) Luigi Formisano et al.   Nature Communications

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

(2019) Jing Xi et al.   Journal of the National Comprehensive Cancer Network

A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC).

(2019) Carlos Henrique dos Anjos et al.   JOURNAL OF CLINICAL ONCOLOGY

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer

(2019) Richard S. Finn et al.   CLINICAL CANCER RESEARCH

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

(2019) George W. Sledge et al.   JAMA Oncology

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

(2018) G N Hortobagyi et al.   ANNALS OF ONCOLOGY

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

(2018) Rinath Jeselsohn et al.   CANCER CELL

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

(2018) Renée de Leeuw et al.   CLINICAL CANCER RESEARCH

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

(2018) Debu Tripathy et al.   LANCET ONCOLOGY

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer

(2018) Nicole Princic et al.   CURRENT MEDICAL RESEARCH AND OPINION

Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.

(2018) Neil Portman et al.   ENDOCRINE-RELATED CANCER

Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.

(2018) Sara M. Tolaney et al.   JOURNAL OF CLINICAL ONCOLOGY

The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial

(2018) Ben O'Leary et al.   Cancer Discovery

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

(2018) Zhiqiang Li et al.   CANCER CELL

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

(2018) Kamal Pandey et al.   INTERNATIONAL JOURNAL OF CANCER

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Abstract P4-13-02: Treatment patterns of post-disease progression in the PALOMA-1/TRIO-18 trial:

(2016) RS Finn et al.   CANCER RESEARCH

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

(2015) Gaia Schiavon et al.   Science Translational Medicine

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

(2015) Barbie Taylor-Harding et al.   Oncotarget

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

(2014) Sadhna R. Vora et al.   CANCER CELL

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE